After this period, we experienced a historical reduction in PSA use on prostate cancer screening by primary doctors and urologists, which was reflected in a significantly increased rate of Gleason 7 or higher, pT3, pT4, and positive surgical margins (PSM). This evidence concerns the gene KLK3 and prostate carcinoma.